103 results
6-K
EX-99.3
CLLS
Cellectis
9 Nov 23
Joint Researchand Collaboration Agreement
4:01pm
, manufacturers, customers or contractors.
Environmental and Health and Safety Matters
Except as Disclosed, (A) neither the Company nor any of its … of such studies or tests. The Company Group has not received any written notifications from any institutional review board, ethics committee or safety monitoring
6-K
EX-99.2
CLLS
Cellectis
9 Nov 23
Joint Researchand Collaboration Agreement
4:01pm
principal suppliers, manufacturers, customers or contractors.
Environmental and Health and Safety Matters
Except as Disclosed, (A) neither … or safety monitoring committee responsible for review, oversight, or approval of any clinical trial involving a Company Group product raising any
6-K
EX-99.1
CLLS
Cellectis
9 Nov 23
Joint Researchand Collaboration Agreement
4:01pm
Recalls, Suspensions, or Withdrawals
Global Safety Database
Article 7 Manufacturing and Technology Transfer
Pre-Option Exercise Date
Post-Option Exercise … , taking into account all scientific, commercial, and other factors, including issues of safety and efficacy, expected and actual cost and time
6-K
EX-99.1
CLLS
Cellectis
6 Nov 23
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
4:35pm
. The first poster is a comprehensive safety review of all 85 patients treated in the Phase 1 ALPHA/ALPHA2 studies in relapsed/refractory (r/r) Large B Cell … Lymphoma (LBCL) and follicular lymphoma (FL) to characterize the overall safety profile when ALLO-647 is added to standard lymphodepletion
6-K
EX-99.1
tmpnjnt9g
6 Nov 23
Current report (foreign)
4:30pm
6-K
EX-99.1
8y4bti20owufxpdn
31 Oct 23
Current report (foreign)
4:35pm
6-K/A
EX-99.1
af12cahx81wi5u8 95
5 Sep 23
Current report (foreign) (amended)
4:32pm
6-K
EX-99.1
bfpow 8p9hu94
7 Aug 23
Current report (foreign)
4:17pm
6-K
EX-99.1
fl2cp64ts8
3 Aug 23
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
4:35pm
6-K
EX-99.1
v1qyryb36c22lviqf0
9 Jun 23
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
4:35pm
6-K
EX-99.1
vty dvs07h
5 Jun 23
Current report (foreign)
4:38pm
6-K
EX-99.1
94fpo
17 May 23
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
4:40pm
6-K
EX-99.1
ijvjy
11 May 23
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
4:35pm
6-K
EX-99.1
1feiuw6
4 May 23
Current report (foreign)
4:26pm
6-K
EX-99.1
xf3aty1hii
17 Apr 23
Current report (foreign)
6:05am
6-K
EX-99.1
e5ruecn91o165 n8g
11 Apr 23
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
4:35pm
6-K
EX-99.1
rsct8gn 2l3zi1ifppk
22 Dec 22
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
4:31pm
6-K
EX-99.1
xsvfdpkihmo zbm8haj
13 Dec 22
Current report (foreign)
8:19am
6-K
EX-99.2
lknwpwqlty83k5
13 Dec 22
Current report (foreign)
8:19am